← Back to Search

Phytochemical

Broccoli Extract for Tobacco-Related Cancer Risk

Phase 2
Recruiting
Led By Julie E Bauman
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Must not have
Pregnant or lactating women. Pregnant women are excluded from this study because the effects of BSSE on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with BSSE, breastfeeding should be discontinued if the mother is treated with BSSE
Uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline and 2, 4, 8, and 12 weeks

Summary

This trial tests if an extract from broccoli seeds and sprouts can help heavy smokers by removing harmful substances from their bodies and protecting their cells from damage. Sulforaphane, derived from broccoli seeds and sprouts, has been shown to induce detoxification enzymes and protect against cancer.

Who is the study for?
This trial is for adult heavy smokers with a significant smoking history who are generally healthy. They must have normal blood counts, liver and kidney function, and if HIV or hepatitis positive, they need controlled viral loads. Women of childbearing age and men must use birth control during the study.
What is being tested?
The trial is testing Avmacol ES (broccoli seed/sprout extract) to see if it helps break down harmful substances from tobacco in heavy smokers. Participants will either receive this supplement or a placebo while their biospecimens are collected for analysis.
What are the potential side effects?
Potential side effects aren't detailed but could include reactions similar to those allergic to compounds like Avmacol ES. Since its effect on fetuses is unknown, pregnant women can't participate.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had hepatitis C but am cured, or I'm being treated with no detectable virus.
Select...
My hepatitis B virus load is undetectable with treatment.
Select...
I have smoked at least 20 pack-years and currently smoke 10 or more cigarettes a day.
Select...
I am able to care for myself but may not be able to do active work.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
I do not have any serious ongoing illnesses like heart failure or uncontrolled infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and 2, 4, 8, and 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and 2, 4, 8, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Detoxification of benzene and acrolein
Secondary study objectives
Bioavailability of BSSE
Dose-response relationship between effective SF dose and the detoxification of benzene and acrolein
Genetic modulators of detoxification of tobacco carcinogens
+2 more
Other study objectives
Inflammation
Modulation of nasal epithelial gene signatures

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (broccoli seed and sprout extract)Experimental Treatment3 Interventions
Patients receive broccoli seed and sprout extract PO QD for 12 weeks in the absence of unacceptable toxicity. Patients undergo the collection of blood, nasal epithelial cell, and buccal cell samples throughout the study.
Group II: Group II (placebo)Active Control3 Interventions
Patients receive placebo PO QD for 12 weeks in the absence of unacceptable toxicity. Patients undergo the collection of blood, nasal epithelial cell, and buccal cell samples throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2020
Broccoli Sprout/Broccoli Seed Extract Supplement
2018
Completed Early Phase 1
~50

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common cancer treatments include chemotherapy, radiation therapy, surgery, and targeted therapies. Chemotherapy works by killing rapidly dividing cells, while radiation therapy uses high-energy particles to damage DNA in cancer cells. Surgery physically removes tumors, and targeted therapies block specific molecules involved in cancer growth. Treatments like broccoli seed and sprout extract focus on detoxification and cellular protection. They work by breaking down and removing carcinogens and protecting cells from damage through mechanisms like the inhibition of histone deacetylase (HDAC) activity. These mechanisms are crucial for cancer patients as they can reduce the toxic burden on the body and protect healthy cells, potentially improving treatment outcomes and reducing side effects.
Plant sprout foods: Biological activities, health benefits, and bioavailability.Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,928 Previous Clinical Trials
41,017,940 Total Patients Enrolled
Julie E BaumanPrincipal InvestigatorGeorge Washington University Cancer Center
2 Previous Clinical Trials
86 Total Patients Enrolled

Media Library

Broccoli Sprout/Broccoli Seed Extract Supplement (Phytochemical) Clinical Trial Eligibility Overview. Trial Name: NCT05121051 — Phase 2
Cancer Research Study Groups: Group I (broccoli seed and sprout extract), Group II (placebo)
Cancer Clinical Trial 2023: Broccoli Sprout/Broccoli Seed Extract Supplement Highlights & Side Effects. Trial Name: NCT05121051 — Phase 2
Broccoli Sprout/Broccoli Seed Extract Supplement (Phytochemical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05121051 — Phase 2
~40 spots leftby Dec 2025